A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
PharmaMar
Columbia University
Ipsen
University Hospital, Antwerp
Prelude Therapeutics
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Quadriga Biosciences, Inc.
Emory University
Swiss Cancer Institute
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Stanford University
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Pediatric Brain Tumor Consortium